References
Sipahi I, Debanne SM, Rowland DY, et al. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol 2010; 11: 627–36
Horwitz RI, Feinstein AR. Exclusion bias and the false relationship of reserpine and breast cancer. Arch Intern Med 1985; 145: 1873–5
Coleman CI, Baker WL, Kluger J, et al. Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials. J Hypertens 2008; 26: 622–9
Pahor M, Furberg CD. Is the use of some calcium antagonists linked to cancer? Evidence from recent observational studies. Drugs Aging 1998; 13: 99–108
Leenen FH, Nwachuku CE, Black HR, et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 2006; 48: 374–84
Effect of enalapril on mortality and development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 1992; 327: 685–91
Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996; 334: 939–45
Grossman E, Messerli FH, Goldbourt U. Antihypertensive therapy and the risk of malignancies. Eur Heart J 2001; 22: 1343–52
Friis S, Felmeden DC, Lip GY. Antihypertensive therapy and cancer risk. Drug Saf 2001; 24: 727–39
Boehringer Ingelheim affirms safety of telmisartan with an analysis of 50,000 patients and strongly disagrees with the publication of Sipahi et al. in Lancet Oncology June 2010 [press release; online]. Available from URL: http://us.boehringer-ingelheim.com/newsroom/2010/06-13-10_telmisartan_safety.html [Accessed 2010 Jul 10]
European Medicines Agency. Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) [online]. Available from URL: http://www.ema.europa.eu/pdfs/human/press/pr/27209310en.pdf [Accessed 2010 Jul 10]
Angiotensin receptor blockers (ARBs): ongoing safety review for cancer risk [online]. Available from URL: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm219185.htm [Accessed 2010 Jul 20]
Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–31
Julius S, Kjeldsen SE, Weber MA. Angiotensin-receptor blockade, cancer, and concerns [letter]. Lancet Oncol 2010; 11(9): 820–1
Acknowledgements
No sources of funding were used to assist in the preparation of this editorial. The author has consulted and/or attended advisory boards for Novartis, Sanofi-aventis, Takeda and Boehringer-Ingelheim in areas unrelated to this editorial.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sica, D.A. Angiotensin Receptor Blockers and the Risk of Malignancy. Drug-Safety 33, 709–712 (2010). https://doi.org/10.2165/11532450-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11532450-000000000-00000